José Baselga

José Baselga was one of the world's foremost authorities on HER2-positive breast cancer and the development of HER2-targeted therapies. As Chief of Hematology/Oncology and later Physician-in-Chief at Memorial Sloan Kettering Cancer Center, he led translational research efforts that fundamentally changed how HER2+ breast cancer is treated. His work on pertuzumab, a second anti-HER2 monoclonal antibody, contributed directly to the landmark CLEOPATRA trial, which demonstrated improved overall survival in metastatic HER2+ breast cancer with the combination of pertuzumab, trastuzumab, and docetaxel. Beyond HER2-targeted therapy, Baselga made major contributions to understanding PI3K pathway alterations in breast cancer and their role in resistance to endocrine and HER2-directed therapies. He led and co-led multiple pivotal clinical trials that informed regulatory approvals of pertuzumab and subsequently influenced neoadjuvant treatment strategies. His translational work bridging genomic insights with clinical applications became a model for precision oncology in breast cancer. Baselga later joined AstraZeneca as Executive Vice President for Oncology R&D, where he guided the development pipeline including antibody-drug conjugates and next-generation targeted agents. He passed away in 2021, leaving behind a scientific legacy that continues to shape breast cancer treatment worldwide.